AI MARKET SCANNING

Compass Therapeutics, Inc.

📅 Next Catalyst: Nov 05, 2026 (☀️ Open) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +1.10%
MAX GAP RECORD +6.88%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $CMPX
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 05, 2026 Earnings Release 2026-11-05 (BEFORE OPEN (07:00)) 🔮 UPCOMING 🔒
Aug 06, 2026 Earnings Release 2026-08-06 (BEFORE OPEN)
+2.12%
May 05, 2026 Earnings Release 2026-05-05 (BEFORE OPEN)
+0.52%
Mar 05, 2026 Earnings Release 2026-03-05 (BEFORE OPEN)
-2.81%
Nov 05, 2025 Earnings Release 2025-11-05 (BEFORE OPEN)
+0.79%
Aug 11, 2025 Earnings Release 2025-08-11 (BEFORE OPEN)
+0.74%
May 07, 2025 Earnings Release 2025-05-07 (BEFORE OPEN)
+0.59%
Feb 27, 2025 Earnings Release 2025-02-27 (BEFORE OPEN)
+1.01%

VOLATILITY & GAP BIAS

AVG GAP MOVE 1.9%
Bullish Gaps (6)
Bearish Gaps (2)
Neutral / Flat (6)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $CMPX

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗